Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A type of drug-resistant tuberculosis that is resistant to all first- and second-line antitubercular drugs tested (isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, ciprofloxacin, capreomycin, kanamycin).
No clinical trials have been registered for totally drug-resistant tuberculosis.
2 publications have been identified in PubMed for totally drug-resistant tuberculosis. Research spans Basic Science / Preclinical (50%) and Gene Therapy / Novel Therapeutics (50%).
Hlanze H (2024). [PMID: 39065108](https://pubmed.ncbi.nlm.nih.gov/39065108/). *Microorganisms*. [Basic Science / Preclinical]
Wahan SK (2024). [PMID: 38460337](https://pubmed.ncbi.nlm.nih.gov/38460337/). *Bioorganic chemistry*. [Gene Therapy / Novel Therapeutics]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 2:57 PM UTC
AI-curated news mentioning totally drug-resistant tuberculosis
Updated Feb 13, 2026
A rare case report highlights the diagnosis and treatment challenges of drug-resistant tuberculosis infection following kidney transplantation. This study underscores the complexities faced in managing such infections in transplant patients.